1. The role of IL-17 rs2275913, IL-17RC rs708567 and TGFB1 rs1800469 SNPs and IL-17A serum levels in patients with lupus nephritis.
- Author
-
Hristova M, Kamenarska Z, Dzhebir G, Nikolova S, Hristova R, Mihova K, Vinkov A, Georgiev T, Pozharashka J, Kaneva R, Savov A, Koundurdjiev A, and Dourmishev L
- Subjects
- Adult, Alleles, Case-Control Studies, Female, Genotype, Humans, Interleukin-17 genetics, Lupus Nephritis blood, Male, Middle Aged, Polymorphism, Single Nucleotide, Receptors, Interleukin-17 blood, Receptors, Interleukin-17 genetics, Retrospective Studies, Transforming Growth Factor beta1 blood, Transforming Growth Factor beta1 genetics, Interleukin-17 blood, Lupus Nephritis genetics
- Abstract
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease and polymorphisms in the cytokine genes and their receptors are thought to influence its development. The aim of this case-control study was to investigate the association of the IL-17A rs2275913, IL-17RC rs708567 and TGFB1 rs1800469 polymorphisms with SLE, its clinical manifestations and the polymorphisms influence on the IL-17A serum levels. Altogether 59 SLE patients with lupus nephritis and 95 healthy controls were genotyped by TaqMan assay. Serum levels were determined by Human IL-17A Platinum ELISA kit. From the studied polymorphisms, only TGFB1 T allele was found to be associated with SLE. Within the patient group, IL-17A GG genotype and TGFB1 -509T allele showed an association with the neurological disease and IL-17RC CC genotype appeared to be associated with lupus arthritis. The IL17A serum levels in the SLE and control groups (7.24 pg/ml and 5.76 pg/ml, respectively) did not show any statistical difference. A weak correlation between IL17A levels and SLEDAI-2K was observed. Our results indicate that IL-17A rs2275913, IL-17RCrs708567 and TGFB1 rs1800469 polymorphisms might play a role in the susceptibility and the clinical manifestations of SLE and IL-17A serum levels should be monitored in the course of the disease. The identification of subsets of SLE with an IL-17-driven disease could improve the therapeutic approach leading to more precise personalized treatment., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF